1. Home
  2. ADEA vs STOK Comparison

ADEA vs STOK Comparison

Compare ADEA & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Adeia Inc.

ADEA

Adeia Inc.

HOLD

Current Price

$22.81

Market Cap

2.3B

Sector

Technology

ML Signal

HOLD

Logo Stoke Therapeutics Inc.

STOK

Stoke Therapeutics Inc.

HOLD

Current Price

$33.57

Market Cap

2.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ADEA
STOK
Founded
1990
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Computer Software: Prepackaged Software
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.3B
2.0B
IPO Year
2020
2019

Fundamental Metrics

Financial Performance
Metric
ADEA
STOK
Price
$22.81
$33.57
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
4
10
Target Price
$29.00
$36.10
AVG Volume (30 Days)
1.1M
616.8K
Earning Date
05-26-2026
04-15-2026
Dividend Yield
0.87%
N/A
EPS Growth
73.68
30.67
EPS
0.99
0.85
Revenue
$443,386,000.00
$36,555,000.00
Revenue This Year
N/A
$428.68
Revenue Next Year
$8.12
N/A
P/E Ratio
$23.11
$42.88
Revenue Growth
17.91
316.34
52 Week Low
$10.59
$5.35
52 Week High
$23.41
$40.22

Technical Indicators

Market Signals
Indicator
ADEA
STOK
Relative Strength Index (RSI) 65.91 46.90
Support Level $12.38 $31.60
Resistance Level N/A $35.75
Average True Range (ATR) 1.08 2.31
MACD 0.25 -0.10
Stochastic Oscillator 90.82 13.43

Price Performance

Historical Comparison
ADEA
STOK

About ADEA Adeia Inc.

Adeia Inc is a consumer and entertainment product/solutions licensing company. It's the only operating segment, being Intellectual Property (IP) Licensing. In the IP segment, the company licenses innovations to companies in the broader entertainment industry and those developing new technologies that will help drive this industry forward. It includes Pay-TV, Consumer Electronics, Connected Car, and Media Platform.

About STOK Stoke Therapeutics Inc.

Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.

Share on Social Networks: